恩格列净对2型糖尿病合并冠心病患者左心室质量的影响:EMPA-HEART CardioLink-6随机临床试验
本研究为随机双盲安慰剂对照试验,纳入97例2型糖尿病合并冠心病患者,随机接受恩格列净10mg/日或安慰剂治疗6个月。主要终点为心脏磁共振测量的左心室质量指数变化,结果显示恩格列净组较安慰剂组显著降低左心室质量指数,并伴有动态血压下降和血细胞比容升高。
要点
- 恩格列净治疗6个月显著降低左心室质量指数,调整后差异为-3.35 g/m2。
- 恩格列净组动态收缩压和舒张压均显著下降,血细胞比容升高。
- 左心室质量降低可能部分解释SGLT2抑制剂的心血管获益。
核心结论
- 在2型糖尿病合并冠心病患者中,恩格列净治疗6个月与左心室质量指数显著降低相关。
- 该效应可能部分解释EMPA-REG OUTCOME试验中观察到的心血管获益。
研究设计与样本
- 随机、双盲、安慰剂对照临床试验,纳入97例40-80岁2型糖尿病合并冠心病患者。
- 参与者随机接受恩格列净10 mg/日(n=49)或安慰剂(n=48)治疗6个月。
- 主要终点为心脏磁共振测量的左心室质量指数从基线至6个月的变化。
主要发现
- 恩格列净组左心室质量指数平均消退2.6 g/m2,安慰剂组为0.01 g/m2,调整后差异-3.35 g/m2(95% CI -5.9至-0.81 g/m2,P=0.01)。
- 恩格列净组动态收缩压调整后差异-6.8 mmHg(95% CI -11.2至-2.3 mmHg,P=0.003),舒张压调整后差异-3.2 mmHg(95% CI -5.8至-0.6 mmHg,P=0.02)。
- 恩格列净组血细胞比容升高(P=0.0003)。
临床怎么用
- 对于2型糖尿病合并冠心病患者,恩格列净可能通过降低左心室质量带来心脏结构获益。
- 恩格列净治疗6个月可显著降低动态血压并升高血细胞比容,临床监测时需关注这些变化。
局限性
- 样本量较小(97例),随访时间仅6个月。
- 研究人群以男性为主(93%),结果推广需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: SGLT2 (sodium-glucose cotransporter 2) inhibitors lower cardiovascular events in type 2 diabetes mellitus but whether they promote direct cardiac effects remains unknown. We sought to determine if empagliflozin causes a decrease in left ventricular (LV) mass in people with type 2 diabetes mellitus and coronary artery disease. METHODS: Between November 2016 and April 2018, we recruited 97 individuals ≥40 and ≤80 years old with glycated hemoglobin 6.5% to 10.0%, known coronary artery disease, and estimated glomerular filtration rate ≥60mL/min/1.73m2. The participants were randomized to empagliflozin (10 mg/day, n=49) or placebo (n=48) for 6 months, in addition to standard of care. The primary outcome was the 6-month change in LV mass indexed to body surface area from baseline as measured by cardiac magnetic resonance imaging. Other measures included 6-month changes in LV end-diastolic and -systolic volumes indexed to body surface area, ejection fraction, 24-hour ambulatory blood pressure, hematocrit, and NT-proBNP (N-terminal pro b-type natriuretic peptide). RESULTS: Among the 97 participants (90 men [93%], mean [standard deviation] age 62.8 [9.0] years, type 2 diabetes mellitus duration 11.0 [8.2] years, estimated glomerular filtration rate 88.4 [16.9] mL/min/1.73m2, LV mass indexed to body surface area 60.7 [11.9] g/m2), 90 had evaluable imaging at follow-up. Mean LV mass indexed to body surface area regression over 6 months was 2.6 g/m2 and 0.01 g/m2 for those assigned empagliflozin and placebo, respectively (adjusted difference -3.35 g/m2; 95% CI, -5.9 to -0.81g/m2, P=0.01). In the empagliflozin-allocated group, there was significant lowering of overall ambulatory systolic blood pressure (adjusted difference -6.8mmHg, 95% CI -11.2 to -2.3mmHg, P=0.003), diastolic blood pressure (adjusted difference -3.2mmHg; 95% CI, -5.8 to -0.6mmHg, P=0.02) and elevation of hematocrit (P=0.0003). CONCLUSIONS: Among people with type 2 diabetes mellitus and coronary artery disease, SGLT2 inhibition with empagliflozin was associated with significant reduction in LV mass indexed to body surface area after 6 months, which may account in part for the beneficial cardiovascular outcomes observed in the EMPA-REG OUTCOME (BI 10773 [Empagliflozin] Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients) trial. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov. Unique identifier: NCT02998970.
引用
- Verma S, Mazer CD, Yan AT, et al. Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial. Circulation. 2019. PMID: 31434508. doi:10.1161/CIRCULATIONAHA.119.042375
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。